Teresa Woodruff

Teresa Woodruff Teresa Kaye Woodruff (born December 7, 1963) is an American molecular and cell biologist, biomedical engineer, ovarian biologist, Endocrinology endocrinologist, Academic administration university administrator, co-holder of 20 U.S. patents, and medical researcher in human reproduction and oncology, noteworthy for her research on effects of cancer therapy on women's health and oncofertility. Among her honors, she was elected in 2006 to the American Association for the Advancement of Science, in 2018 to both the National Academy of Medicine and the National Academy of Inventors, in 2020 to the American Academy of Arts and Sciences, and in 2026 to both the American Philosophical Society and the Royal Society. Quotes The war on cancer has been an aggressive one and successful treatment is associated with significant complications. These complications include a physical toll on the cardiovascular system, bone biology, movement of lymph in the appendages, and the loss of organ function. Complications can also involve psychological issues such as depression, anxiety, uncertainty, isolation, and an altered body image. The Cancer survivor survivor can also face social and existential crises such as a fear of engaging in interpersonal relationships, problems with Health insurance health and life insurance, job loss, problems with school and finances, an altered sense of purpose, and a different appreciation of life. One of the main complications of modern cancer treatment, particularly for young men, women and children is the Fertility preservation impact of cancer treatment on future fertility. Chapter 1. The emergence of a new interdiscipline: oncofertility by Teresa K. Woodruff Oncofertility fertility preservation for cancer survivors Volume 138 of Cancer Treatment and Research Springer Science & Business Media 9780387722924 2007 3–11 https://books.google.mw/books?id=gcv3IFYulRcC&pg=PA3 (quote from p. 3; 263 pages; edited by Teresa K. Woodruff & Karrie Ann Snyder} In 2007, I was asked by the University of Calgary to participate in a symposium called 'Pushing the Boundaries—Advances that Will Change the World in 20 Years'. My topic was oncofertility, a word I had just coined to describe the intersection of two disciplines—oncology and Fertility#In medicine fertility—and I was thrilled to share my passion for this new field and help young women with cancer protect their future reproductive health. Fertility preservation in the cancer setting lacked a concerted effort to bridge the disciplines in an organized manner. In early 2015, I was delighted to deliver a presentation for the Society for Reproduction and Fertility titled 'Sex in Three Cities', where I gave an update on the oncofertility movement, a remarkable cross-disciplinary, global collaboration created to address the fertility preservation needs of young cancer patients. During my tour of the UK, I was impressed by the interest among the society and its members to engage colleagues outside the discipline as well as the public in a dialogue about cutting-edge reproductive science. In this invited review, I will describe the work of the Oncofertility Consortium to provide fertility preservation options in the cancer setting and accelerate the acceptance of this critical topic on a global scale. I hope that one day this word and field it created will change the world for women who had been left out of the equation for far too long. Oncofertility: a grand collaboration between reproductive medicine and oncology Reproduction 150 3 September 2015 S1-S10 https://pubmed.ncbi.nlm.nih.gov/26130814/ 10.1530/REP-15-0163 Human reproductive technologies have relied on recombinant Follicle-stimulating hormone FSH as the main tool of stimulating Ovarian follicle follicles, and ... overcome the inhibin B break in the system, resulting in a full cohort of follicles and therefore multiple mature Oocyte eggs. Easy, elegant endocrinology except for the fact that producing large numbers of eggs is not the goal, and In vitro fertilisation IVF remains incredibly inefficient. Instead of quantity, the field of fertility regulation needs quality—a single fertilizable, high-quality egg. The key to the next breakthrough in the field could be directly managing endogenous FSH and its very specific glycosylated variants that are differentially regulated at different cycle stages through Activin and inhibin inhibins A and B ... Indeed, creating a suite of next-generation small molecules that regulate release and inhibition of endogenous FSH should create more tailored interventions compared to the approaches of today. In this way, inhibin B and its co-receptor close one chapter and usher in a new generation of discoveries. Science Advances Closing the loop on female fertility https://pmc.ncbi.nlm.nih.gov/articles/PMC11323799/ December 15, 2021 7 51 10.1126/sciadv.abn1373 eabn1373 External links Teresa K Woodruff, Ph.D. The Oncofertility Consortium, Michigan State University (oncofertility.msu.edu) https://oncofertility.msu.edu/about/dr-teresa-k-woodruff-phd/ January 6, 2025 An Interview with Dr. Teresa Woodruff (by Jamie Durana) National Academy of Medicine https://nam.edu/news-and-insights/teresa-woodruff-interview/ Category:1963 births Category:Living people Category:Biologists from the United States Category:Fellows of the American Academy of Arts and Sciences Category:Members of the American Philosophical Society Category:Members of the National Academy of Medicine Category:Women academics from the United States Category:Women scientists from the United States